If you are not happy with the results below please do another search
Matthew W. Reynolds, Ph.D., vice president, scientific affairs, real world solutions, IQVIA explains how RWE evidence platforms can provide a greater picture of a disease’s progression as well as a blueprint for future outbreaks.
As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody Tecentriq (atezolizumab) for a specific type of previously untreated metastatic bladder cancer.
Bristol Myers Squibb is terminating a seven-year-old gene therapy collaboration to develop potential treatments for congestive heart failure with uniQure N.V. valued at $1 billion.
Twitter Inc. has rolled back a policy that was aimed at tackling misinformation related to COVID-19 on the social media platform, lending itself to the risk of a potential surge in false claims even as cases rise in China and some parts of the world.
AstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company for $320 million.
The agency will provide end-to-end omnichannel offering and capabilities across healthcare that will support and complement the network’s agencies and clients in the region.
England’s government agency responsible for responding to public health emergencies said mistakes at a testing laboratory resulted in tens of thousands of positive COVID-19 cases reported as negative may have led to the deaths of 20 people.
One day ahead of a data presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Science reported a second patient death has been linked to Eisai and Biogen’s lecanemab.
Visconti will oversee all aspects of the agency’s marketing intelligence services, leading a team of accomplished specialists who provide data, analysis, insights, multi-touch attribution models, predictive data intelligence, and success metrics for enhancing client and agency decision-making and optimizing the impact of client marketing campaigns.
The deal, valued at $615 million, will expand Boston Scientific’s portfolio of gastric devices.